A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Balana, Carmen
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). [electronic resource] - Neuro-oncology 12 2020 - 1851-1861 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-5866
10.1093/neuonc/noaa107 doi
Antineoplastic Agents, Alkylating--adverse effects
Brain Neoplasms--drug therapy
Disease-Free Survival
Glioblastoma--drug therapy
Humans
Temozolomide--adverse effects
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). [electronic resource] - Neuro-oncology 12 2020 - 1851-1861 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-5866
10.1093/neuonc/noaa107 doi
Antineoplastic Agents, Alkylating--adverse effects
Brain Neoplasms--drug therapy
Disease-Free Survival
Glioblastoma--drug therapy
Humans
Temozolomide--adverse effects